Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

BioSante Pharmaceuticals nets $45.1mm through FOPO

Executive Summary

BioSante Pharmaceuticals Inc. (women’s health and cancer therapeutics) has netted $45.1mm through the follow-on public offering of 16mm common shares at $3. Some of the funds will be used to continue Phase III studies of LibiGel, a once-daily transdermal testosterone gel for hypoactive sexual desire disorder in women.
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
  • Pharmaceuticals
    • Drug Delivery
      • Transdermal
    • Vaccines
Deal Status
  • Final
Deal Type
  • Financing
    • FOPO

Related Companies